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Coccidioidomycosis (CM), also known as
Valley fever, is caused by the dimorphic fungus
Coccidioides immitis, endemic to the southwest-
ern United States, Mexico, and Central and
South America. In California before 1991,
approximately 400 to 500 new cases were
reported annually. During 1991 to 1994, the
number of cases increased dramatically, with
1,200 new cases reported in 1991, 4,541 in 1992,
and 4,137 in 1993 (1-4).
C. immitis is a soil-dwelling organism that
blooms after the rainy season. Infection usually
occurs in the dry season, when arthroconidia
become airborne and can be inhaled by the host.
In California in 1991, increased rainfall
following a drought allowed increased fungal
proliferation, resulting in an increased rate of
infection. The 1994 Northridge earthquake led to
an increase in infections associated with
landslides and dust clouds that aerosolized
arthroconidia. Increased risk for symptomatic
CM was directly proportional to time spent in the
dust cloud (5).
Of those infected, an estimated 60% are
asymptomatic, with the only evidence of
exposure being delayed-type hypersensitivity
(DTH) reaction to a coccidioidal antigen skin
test. Of the symptomatic patients, 90% to 99%
experience only mild flulike symptoms. More
severe chronic pulmonary disease or dissemi-
nated infection beyond the thoracic cavity occurs
in 1% to 10% of symptomatic cases, depending on
ethnicity (N. Ampel, pers. comm.). Disseminated
CM is particularly devastating and usually
requires lifelong antifungal treatment. Risk
factors include male sex, compromised immune
status, pregnancy, diabetes, advancing age, and
smoking (6-9).
Risk for disseminated CM seems to differ
according to ethnicity (9). For example, during
the 1977 windborne outbreak of CM in the
nonendemic-disease region of Sacramento
County, California, the rate per 100,000 of acute
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Coccidioidomycosis, a mild flulike illness in approximately 40% of infected persons,
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HLA class II  DRB1*1301 allele marks a pre-disposition to severe disseminated disease
in each of the three groups. Reduced risk for severe disease is associated with
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DQB1*0602 among African-Americans. These data support the hypothesis that host
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Table 1. Coccidioidomycosis participants, by ethnicity
and severity of disease
African
Cauca- His- Ameri-
Cases sians panics cans Other Total
Severe      27   50      25 7 109
Mild      50   32        1 0   83
Total      77   82      26 7 192
Outside
  controls
ABO 8,962 335 3,146
HLA    107 115    241
(109 for
 DPB1)
symptomatic pulmonary CM among African-
American men compared with Caucasian men
was 67 versus 19 (ratio 3.5:1) and of
disseminated CM was 23.8 versus 2.5 (ratio
9.1:1). These differences could not be explained
by differential exposure (11). More recently, in
the endemic area of Kern County, California,
African-American men had an adjusted odds
ratio for disseminated CM of 28 (95% confidence
interval [CI] 2-385), higher than that of any
other ethnic group. No environmental or
occupational exposures were associated with
either severe pulmonary or disseminated disease
(9). Both the range of response given C. immitis
exposure and the apparent variation in
susceptibility among ethnic groups suggest that
genetic factors influence the development of
symptomatic, severe, and disseminated CM.
T-cell-mediated immunity is important in
the elimination of the fungus, but it eventually
diminishes if the disease progresses (12,13).
Although little is known about the role of T-cells
in eliminating C. immitis, activated T-cells elicit
a DTH inflammatory response, indicating a Th1-
type response (14). While DTH reactivity is
regulated by class II HLA interactions with T
cells, the host immune response to intracellular
pathogens is primarily regulated by class I HLA
molecules. HLA genes are therefore prime
candidates for the study of host genetic
influences on the severity of CM. Some studies
have shown disseminated CM to be associated
with HLA antigens (A-9, B-5) and ABO blood
group B (6,7,15,16). Both African-Americans and
Filipinos have greater frequency of the B blood
group and HLA-A9 than do Caucasians (16).
Kern County, where CM is highly endemic,
contributed substantially to the 1991 to 1994
epidemic in California. We investigated the role
of genetic factors in CM in a case-control study of
persons from Kern County among patients with
severe disseminated disease or mild disease.
This study explored the possible association of
HLA class II alleles and haplotypes and ABO
phenotypes with severity of CM disease in three
ethnic groups.
Methods and Study Design
Participants
Patients were recruited from the Kern
County Health Department and Kern Medical
Center. Severe cases (n = 109) were defined as
extrapulmonary disseminated CM, with disease
spreading beyond the thoracic cavity, including
prevalent and incident cases seen or diagnosed
from 1995 through 1997. Mild cases (n = 83) were
diagnosed during 1995 to 1996, with uncompli-
cated disease limited to the lung (or lymph nodes
draining the lung) and not requiring hospitaliza-
tion (Table 1). Incident cases, which had
laboratory evidence of acute infection, were
detected during a population-based surveillance
study of CM in Kern County (11). All diagnoses
were laboratory confirmed by serologic testing,
enzyme immunoassay  ([EIA], immunodiffusion,
and complement fixation), or culture at the Kern
County Health Department Laboratory.
For controls, data from ethnically and
geographically matched populations were ob-
tained from the literature (Table 1). For ABO
phenotype comparisons, populations from San
Francisco, were selected (17). Molecular data for
comparing HLA allele frequencies were selected
from healthy Caucasians from California (18),
Hispanics from Los Angeles (19), and African-
Americans from New York (20).
Genetic Testing
Standard ABO antigen blood typing was
performed at the Kern County Health Depart-
ment laboratories. All persons were typed for
four HLA class II loci (DRB1, DQA1, DQB1, and
DPB1) by molecular methods (21-24).
Statistical Analyses
For the HLA data, Hardy-Weinberg geno-
typic proportions were calculated to examine the
equilibrium in each locus (25). Methods of testing
genotypic ratios in the ABO system with the674 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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Table 2. Hardy-Weinberg test results (p values) for HLA
class II loci, by ethnicity and severity of diseasea
Cases DRB1DQA1 DQB1 DPB1     N
Hispanic, Severe 0.34 0.18 0.38 0.27 50
Hispanic, Mild 0.12 0.11 0.002 0.045 32
Caucasian, Severe 0.09 0.14 0.38 0.008 27
Caucasian, Mild 0.12 0.14 0.11 0.022 50
African-American, 0.63 0.80 0.67 0.31 25
  Severe
aNumbers in bold indicate alleles not in Hardy-Weinberg
equilibrium for a particular group and locus.
Table 3. Blood group antigen frequencies for
coccidioidomycosis, by ethnicity and severity of disease
Phenotype
Ethnic group A AB B O     N
Hispanica Severe 0.24 0.02 0.12 0.62      50
Mild 0.53 0.00 0.00 0.47      32
Controlsb 0.13 0.04 0.27 0.56    335
Caucasian Severe 0.48 0.04 0.04 0.44      27
Mild 0.46 0.02 0.12 0.40      50
Controlsb 0.41 0.03 0.11 0.45 8,962
African- Severe 0.12 0.04 0.16 0.68      25
  American Controlsb 0.28 0.04 0.19 0.50 1,540
aABO phenotype distribution for cases and controls among
Hispanics, p  < 0.001
bPopulation control frequencies from Mourant, 1976 (17)
recessive O allele were followed (26). HLA
haplotype frequencies were estimated for each risk
group by ethnicity and disease severity by using
standard maximum likelihood methods (27,28).
ABO phenotype and allele frequencies and
HLA class II allele and haplotype frequencies
were compared by using 2 x k contingency tables
that give an overall G-statistic, where k is the
total number of alleles present in the comparison
groups for a particular locus. All analyses were
stratified by ethnicity. Comparing severe cases
with mild cases assessed risk for disease
progression after symptomatic infection, and
comparing severe or mild cases with controls
examined risk for disease severity and infection
relative to each ethnic population. In any
comparison, alleles present in fewer than three
persons were pooled into a combined class of rare
alleles. If the overall comparison showed
statistically significant heterogeneity, the un-
derlying difference was examined among
individual alleles, phenotypes, or haplotypes by
using the chi-square statistic, with odds ratios
(OR) and Yates corrected or Fishers p values
reported. Since only one African-American with
mild disease was enrolled, analyses for African-
Americans were limited to comparing severe cases
with controls.
Interaction effects of ABO and HLA alleles
associated with disease were assessed with the
Mantel-Haenszel chi-square test and weighted
OR by using EpiInfo version 6.01.
Results
Hardy-Weinberg Tests
Severe and mild cases were examined for
deviations from Hardy-Weinberg equilibrium to
validate the source populations and genotyping
and to detect alleles that might be associated
with disease. In each instance, the HLA loci
DRB1 and DQA1 genotypic ratios were in
equilibrium (Table 2). However, the DPB1 locus
for mild cases among Hispanics and mild and
severe cases among Caucasians and the DQB1
locus for Hispanics with mild cases were not in
equilibrium (p <0.05, Table 2). For DPB1 among
Caucasians with mild cases, DPB1*0301-*0401
was less common than expected (none observed
vs. three expected). For DPB1 for mild cases
among Caucasians and Hispanics, genotypes
with the *1401, *1601, and *4601 alleles were
observed more often than expected. Other loci
not in Hardy-Weinberg equilibrium (p <0.05) had
no significant deviations at individual genotypes.
ABO phenotype frequencies did not depart
from Hardy-Weinberg equilibrium except for the
large Caucasian control sample, which differed
at p = 0.04, indicating a small deviation from
equilibrium (data not shown).
Testing for Allelic Association
ABO blood types were analyzed by compar-
ing the blood type phenotype to disease status
(severe, mild, control) in contingency table tests.
No differences between groups were seen for
Caucasians (p = 0.80). This was also true for
African-Americans when patients with severe
disease were compared with controls (p = 0.21).
Blood group phenotype frequencies among
Hispanics, however, were highly heterogeneous
with respect to disease status (p < 0.001) (Table 3).
Among affected persons with either severe or
mild disease, the A phenotypes were more
frequent (OR = 1.71, p = 0.18 and OR =
5.53, p <10-4, respectively) and the B phenotypes
less frequent (OR = 0.36, p = 0.021 and OR = 0,
p <10-3, respectively) than among controls.
Comparing severe versus mild cases among
Hispanics, the A phenotypes were associated with
decreased risk (OR = 0.31, p = 0.024) and the B675 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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Table 4. Significance levels from contingency table
analyses of allele distributions for coccidioidomycosis,
by ethnicity and severity of diseasea
Severe Severe Mild
vs. vs. vs.
Ethnic group Locus    mild     control control
Caucasians DQA1 0.231    0.069    0.048
DQB1 0.024    0.02    0.002
DRB1 0.075    0.12  <0.001
DR-DQ 0.031  <0.001  <0.001
DPB1 0.781    0.215    0.355
Hispanics DQA1 0.074       ---       ---
DQB1 0.41    0.003    0.16
DRB1 0.63  <0.001    0.16
DR-DQ 0.29  <0.001    0.02
DPB1 0.024    0.403    0.026
African- DQA1   ---    0.89       ---
  Americans DQB1   ---    0.34       ---
DRB1   ---    0.001       ---
DR-DQ   ---  <0.001       ---
DPB1   ---    0.38       ---
aSignificant test results are in bold
Table 5. HLA alleles and haplotypes associated with severity of coccidioidomycosis, by ethnicity
  Caucasian   Hispanic   African-American
Locus S v. Ma S v. C M v. C    S v. M S v. C M v. C   S v. C
a. Alleles associated with decreased risk
DQB1     *0402b      *0604b       *0604b      *0302b
    *0504b
DRB1        *0301c      *0407c     *1501c
       *1104b      *0408b
DRB1-DQB1 *0700-*0303b *0301-*0201b *0301-*0201b *0407-*0302c *0301-*0201c *1501-*0602c
*0404-*0302b *1104-*0301b *0700-*0201b *1402-*0301c
*0700-*0303b *1101-*0301c
*1302-*0604b *0101-*0501b
DPB1        *0501b
b. Alleles associated with increased risk
DQB1      *0602b        rareb         *0504d      *0602c
          rared      *0603b
DRB1         *0303c      *1103c     *1301c
       *1301b     *1301c      *1503c
          rared      *1406c        rarec
        rareb
DRB1-DQB1 *1301-*0602b *1301-*0602d *1301-*0504c *0700-*0301c         rarec *1301-*0501c
*0700-*0201b *1302-*0201c *1301-*0603b *1503-*0602c
       rared *0303-*0201c *1302-*0301c
          rareb *1406-*0301c
        rareb
DPB1 *0101b        rareb
*0201b
aS, severe cases; M, mild cases; C, outside controls
b p < 0.05
c p < 0.01
dp < 0.001
phenotypes with increased risk (OR >5.2, Fishers
p = 0.039) of disseminated disease (Table 3).
Several of the HLA class II loci showed
overall heterogeneity in the allele frequencies
tested pairwise among the three disease status
categories (Table 4). Effects occurred in all three
ethnic groups. Significant effects occurred more
extensively and with greater significance in
comparisons of cases versus controls than in
comparisons of severe cases versus mild cases for
DQB1, DRB1, and DR-DQ haplotype. This result
might be due to the higher sample size in the
controls, allowing greater power in comparisons
with this group.
Significant HLA allelic and haplotypic
associations  differed for each ethnic group
(Table 5). However, Caucasians and Hispanics
share a haplotype, DRB1*0301-DQB1*0201,
associated with reduced risk for disease. Among
Caucasians, both mild and severe cases had this
effect when compared with controls (OR = 0.2, p
= 0.012 and OR = 0.1, p = 0.007, respectively).
Among Hispanics, the effect was observed only
for mild cases versus controls (OR = 0.1, p = 0.007).
The DRB1 allele, *1301, was associated with
increased risk for disease in all three ethnic
groups compared with controls. For Caucasians,
mild cases were associated with this allele (OR =
2.6, p = 0.028), whereas severe cases were
associated among Hispanics (OR = 4.9, p = 0.01)
and African-Americans (OR = 4.2, p = 0.008). The
DRB1-DQB1 haplotypes containing DRB1*1301
in each group were also associated with
increased risk, although the DQB1 alleles in the
haplotypes differed (Table 5).676 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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Among African-Americans, only DRB1
showed overall allelic heterogeneity (p = 0.001).
DRB1*1301, *1501, and *1503 each contributed
to the risk for severe disseminated disease (OR =
4.2, p = 0.008; OR = 0.1, p = 0.002; and OR = 10.2,
p = 0.01, respectively). Comparing haplotype
frequencies increased the significance of
these  differences (p <0.001). DRB1-DQA1-DQB1
haplotypes *1301-*0102-*0501 and *1503-*0102-
*0602 were associated with higher risk (OR =
10.4, p = 0.003 and OR = 10.2, p = 0.01,
respectively), and *1501-*0102-*0602 was asso-
ciated with lower risk (OR = 0.1, p = 0.003) of
severe disseminated disease. Rare alleles of
DRB1 and DRB1-DQB1 haplotypes were
consistently associated with increased risk in all
three ethnic groups (Table 5).
The joint effects of HLA DRB1*1301 and
blood group A or B phenotype on progression to
disseminated disease were tested in Hispanics,
which had substantial ABO effects. When severe
cases were compared with mild cases, an effect
persisted for the A phenotype (ORMH = 0.30,
p = 0.02, data not shown).
Discussion
Except for the Native American genetic
component of the Hispanic (Mexican-American)
population, the ethnic groups examined show no
evidence of an evolutionary response to the
pathogenic threat of C. immitis. Despite this
fact, evidence is presented that for each ethnic
group, allele and haplotype distributions at HLA
and ABO genes vary according to disease
outcome. Substantial differences at these loci
were identified in the risk for symptomatic
disease after infection with C. immitis. The
differences in susceptibility associated with ethnic
background can be attributed to genetic
influences. In certain instances, identical HLA
alleles were observed among Hispanic, Caucasian,
and African-American persons. In contrast, only
Hispanic participants demonstrated ABO effects.
Effects could be observed if controls
inadequately represent cases. Controls were
matched as closely as possible to cases by
ethnicity and geographic proximity. Cauca-
sians were defined as persons of mixed
European descent, while Hispanics were
defined as Mexican-Americans. The African-
Americans were persons with European-
African admixture. For ABO comparisons, all
case patients were from California. For HLA,
all Hispanic and Caucasian persons were from
California.
The lack of cases of mild disease noted among
African-Americans may be due to ascertainment
bias or biologic cause. Severe cases, which
require medical management, are much more
likely to come to medical attention and be
identified by the study. Because mild infections
are self-limiting, some persons may not seek
medical care and may not be identified. In a
population-based surveillance study of CM in
Kern County between 1995 and 1996 (11),
African-Americans comprised 6% of all mild
cases and 22% of all disseminated cases
(Table 1). By comparison, Hispanics comprised
38% of mild cases and 39% of disseminated cases
in the surveillance study versus 39% and 46%,
respectively, in the present study. Thus mild
cases among African-Americans are
underrepresented in this study by approxi-
mately fourfold.
Patients with mild disease may respond
differently, depending on ethnic background, in
seeking treatment, use of medical care, or
response rate to study participation. Statistics on
use of health-care services in the United States
during 1996-1997 showed that the time since last
physician contact was nearly identical for
Caucasians and African-Americans. Overall,
African-Americans had similar numbers of
ambulatory health-care visits per person per
year (3.3 for Caucasians versus 3.9 for African-
Americans) (29). However, a greater propor-
tion of visits by African-American patients was
to emergency rooms or hospitals as outpatients
(an average of one visit per person per year for
African-Americans versus 0.6 for Caucasians)
(29). If this pattern of health-care use is similar
in Kern County, then the >10:1 difference in the
frequency of mild cases among Caucasians
versus those among African-Americans in this
study cannot be explained by ascertainment bias.
An alternative explanation is that mild CM is
intrinsically rare among African-Americans
compared with Hispanics and that most
exposures to C. immitis in African-Americans
result in severe disseminated disease. The
surveillance study indicates that mild cases are
more rare among African-Americans.
ABO Effects
ABO blood group is one of the first human
genetic polymorphisms identified (30). Numerous677 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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studies (17,31) have examined the relationship
between ABO and disease, with inconclusive
results. The distribution of A and B antigens in
the body, the differences between the two alleles
(32), and the existence of A, B, and O alleles in
aboriginal human populations worldwide (except
the New World) point to the evolutionarily
demonstrated functional importance of this
system. The association of CM with blood group
phenotypes between the mild and severe cases
among Hispanics, as well as between these cases
and controls, again suggests a direct role for
blood group antigens in disease susceptibility.
Previous studies reported that the B blood
group was more frequent among persons with
severe disseminated cases than among those
with mild cases (7,16). These analyses did not
consider ethnicity. Our results among Hispanics
support earlier findings. However, the frequency
of the B phenotype among severe cases (14%) and
mild cases (0%) is lower than the frequency (31%)
reported in the Hispanic population from San
Francisco (17). Assuming the controls were
adequately matched to cases, the lack of blood
group B in mild cases suggests perceived risk
when compared with severe cases. For Cauca-
sians, an opposite (nonsignificant) trend is
observed: the frequency of blood group B
phenotypes in the population is approximately
14%, the same as among persons with mild cases
in this study, and relatively fewer persons with
severe cases (8%) have this antigen. The frequency
of B phenotypes among African-Americans with
severe cases (20%) is similar to that observed in
the control population (23.4%) (17).
The A blood group phenotypes are more
frequent among Hispanics with cases than
among controls, but less frequent among those
with severe cases than mild cases. This antigen
appears to have the opposite effect on disease
expression and severity to that of the B antigen.
Culture filtrates of C. immitis were reported
to contain blood group A activity (33). If this is
true, C. immitis A-like polysaccharides may be
adsorbed to the surface of host cells and cross-
react with A antibodies to give false positivity.
Certain instances of acquired B expression have
been documented in persons with advanced age
or disease (30). Also noted is cross-reactivity of
anti-B antibodies with polysaccharides from
Escherichia coli O86, which can induce false B
reactivity in infected persons (30).
Hardy-Weinberg genotypic frequencies for the
ABO system were in equilibrium among Hispanics,
an observation that does not support these
explanations.
Alternatively, the immune systems of
persons with A phenotypes may not recognize
the A-like coccidioidal antigens as foreign. This
may allow infection to be established without
immunologic challenge to these antigens,
leading to increased risk for symptomatic
disease. The lower frequencies of B phenotypes
may reflect the increased frequency of A
phenotypes in this study.
HLA Effects
When analyzing HLA allele and haplotype
distributions across ethnic groups, one looks for
unifying themes that might implicate a
particular allele or haplotype in a universal role
for susceptibility in all groups. Such a finding
would suggest that the set of molecules
themselves is functionally responsible for the
observed associations. The specificity of class II
molecules depends on the alleles of the
heterodimer subunits, which differ in their
combined ability to recognize antigenic peptides.
HLA polymorphisms defining allelic variation
generally occur in the amino acid sites found in
or near the peptide binding groove, thus
affecting the interaction of the HLA molecule
with the peptide or with the T-cell receptor.
Some HLA alleles bind and present particular
antigens to T cells better than other alleles. In
this context, persons who present coccidioidal
antigens more effectively to T cells may be able to
eliminate the fungus before the disease
progresses to more severe forms.
We found that the DRB1*1301 allele was
associated with increased risk for disease in
comparisons of mild or severe cases versus
controls among all three ethnic groups.
However, the DQA1-DQB1 portions of the
haplotypes associated with this allele and with
risk for each ethnic group were not the same.
This suggests that the DRB1*1301 allele itself
might be responsible for increased risk for
symptomatic disease, regardless of ethnic
background. DRB1*1301 has previously been
associated with reduced risk for perinatal HIV
infection (34,35) and decreased risk for progression
of perinatally acquired HIV disease (36).
For both Caucasians and African-Americans,
the strength of the DRB1*1301 association
increases when more specifically defined by the678 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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DRB1-DQA1-DQB1 extended haplotype. For
African-Americans with severe cases, this
haplotype is *1301-*0102-*0501 (OR = 10.4, p =
0.003 vs. controls). Among Caucasians with
severe cases, the extended haplotype is *1301-
*0103-*0602 (OR = 35.0, p = 0.0003 vs. controls)
and for mild cases is *1301-*0103-*0504 (OR =
18.1, p = 0.002 vs. controls). DQA1*0103 alone is
associated with increased risk for disease.
However, the haplotype *1301-*0103-*0603 is
common among both cases and controls and
neutral for CM risk. Among Hispanics with
severe cases, the marker for severe disease rishk is
the extended haplotype *1301-*0103-*0603 (OR
= 3.6, p = 0.05 vs. controls). These data suggest
that DRB1*1301-DQA1*0103 may predispose
Caucasians to symptomatic infection, but this risk
is modified by DQB1 alleles. DQB1*0603 may
negate this risk in Caucasians, while *0504
decreases or *0602 increases the risk for
progression to severe disseminated disease. This
stepwise mechanism is not evident from results
for the other ethnic groups.
For Caucasians and Hispanics with cases,
DRB1*0301-DQB1*0201 was associated with
lower risk for disease than among controls,
consistent with a protective effect of this
haplotype. The DRB1*0301 allele has been
associated with autoimmune disease risk in
Caucasians (37). Among African-Americans, the
*1501-*0602 haplotype was associated with
lower risk for severe disease.
Another common theme observed in these
data is that differences can be attributed in
several comparisons to rare alleles or haplotypes
present in a higher proportion of cases (either
mild or severe) than controls. Since they
otherwise share no particular molecular fea-
tures, this may represent absence of alleles that
specifically protect from infection by C. immitis.
Lack of consistency for HLA associations
across ethnic groups does not preclude involve-
ment of these alleles in specific populations, as
HLA effects may produce disease susceptibility
across ethnic groups as well as within one ethnic
group. For example, HLA class II haplotypes
predispose to insulin-dependent diabetes melli-
tus among Caucasian and Japanese (38). Among
Caucasians, DR3 haplotypes are highly signifi-
cantly associated with disease. This is not true
among the Japanese, because DR3 haplotypes
are extremely rare in the Japanese population,
in which the associated haplotypes are DR4 and
DR9. Thus, HLA alleles and haplotypes may be
associated with disease in only one ethnic group.
Future studies could better address the risk
for symptomatic CM by recruiting controls who
are resistant to disease, i.e., persons with
positive coccidioidal antigen skin tests who were
not hospitalized for their infections. This
selection would identify a more suitable control
group for comparison with patients who have
either mild or severe forms of CM in investigating
risk factors for disease progression.
Our data support the hypothesis that host
genes, in particular HLA class II and ABO blood
group, play a complex role in susceptibility to
severity of CM. Identifying genes that influence
risk for developing severe disseminated CM may
aid prevention efforts by targeting persons at
high risk for disseminated disease who should be
monitored closely after potential exposures, and
may also aid in study design to test potential
vaccines for efficacy, once candidate vaccines
become available (39-41).
Acknowledgments
We thank Arthur Reingold for academic support and
critical review of the manuscript and Gretchen Rothrock for
administrative support, Kirt Emery and Denise Rogers for
local epidemiologic support, Kern Medical Center staff for
clinical support, and David Lee, Kathy Schultz, and Thomas
Featherston for technical support.
This work was done with support from the Centers for
Disease Control and Prevention (CDC#584).
Dr. Louie is an epidemiologist and research scien-
tist at the University of California, Berkeley, School of
Public Health. Her areas of expertise are in genetic epi-
demiology and infectious diseases. Dr. Louies current
research focuses on genetic risk factors for AIDS, tuber-
culosis, and coccidioidomycosis, including aspects of host-
pathogen genetic interaction.
References
  1. Pappagianis D, Sun RK, Werner SB, Rutherford GW,
Elsea RW, Miller GB, et al. Coccidioidomycosis
United States, 1991-1992. MMWR Morb Mortal Wkly
Rep 1993;42:21-4.
    2. Pappagianis D. Marked increase in cases of
coccidioidomycosis in California: 1991, 1992, and 1993.
Clin Infect Dis 1994;19 Suppl 1:S14-8.
  3. Pappagianis D, Feldman G, Billimek M, Mascola L,
Werner SB, Jackson RJ, et al. Coccidioidomycosis
following the Northridge earthquakeCalifornia,
1994. MMWR Morb Mortal Wkly Rep 1994;43:194-5.
  4. Jinadu BA, Welch G, Talbot R, Caldwell J, Johnson R,
Blume D, et al. CoccidioidomycosisCalifornia, 1991-
1993. MMWR Morb Mortal Wkly Rep 1994;43:421-3.679 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
Research
  5. Schneider E, Hajjeh RA, Spiegel RA, Jibson RW, Harp
EL, Marshall GA, et al. A coccidioidomycosis outbreak
following the Northridge, Calif, earthquake. JAMA
1997;277:904-8.
    6. Galgiani JN, Cohen IM. Coccidioidomycosis in renal
transplant recipients: blood group, diabetes, and tissue
type as risk factors. Current chemotherapy and infectious
disease. Proceedings of the 11th International Congress of
Chemotherapy and the 19th Interscience Conference on
Antimicrobial Agents and Chemotherapy. Boston (MA):
American Society for Microbiology; 1980. p. 992-4.
    7. Cohen IM, Galgiani JN, Potter D, Ogden DA.
Coccidioidomycosis in renal replacement therapy. Arch
Intern Med 1982;142:489-94.
    8. Galgiani JN. Coccidioidomycosis. West J Med
1993;159:153-71.
  9. Pappagianis D. Epidemiology of coccidioidomycosis. In:
McGinnis M, editor. Current topics in medical
mycology. New York: Springer Verlag; 1988. p. 199-238.
10. Flynn NM, Hoeprich PD, Kawachi MM, Lee KK, Lawrence
RM, Goldstein E, et al. An unusual outbreak of windborne
coccidioidomycosis. N Engl J Med 1979;301:358-61.
11. Rosenstein N, Werner SB, Kao A, Emery K, Rogers D,
Vugia D, et al. Coccidioidomycosis: risk factors for
severe pulmonary and disseminated disease. Kern
County, California. Proceedings of the 35th Annual
Meeting of the Infectious Diseases Society of America;
1997 Sept 13-17; San Francisco, California; 1997.
12. Catanzaro A, Spitler LE, Moser KM. Cellular immune
response in coccidioidomycosis. Cell Immunol
1975;15:360-71.
13. Cox RA, Vivas JR, Gross A, Lecara G, Miller E, Brummer
E. In vivo and in vitro cell-mediated responses in
coccidioidomycosis. I. Immunologic responses of persons
with primary, asymptomatic infections. American Review
of Respiratory Disease 1976;114:937-43.
14. Mosmann TR, Coffman RL. Heterogeneity of cytokine
secretion patterns and functions of helper T cells. Adv
Immunol 1989;46:111-47.
15. Scheer M, Opelz G, Terasaki P, Hewitt W. The
association of disseminated coccidioidomycosis and
histocompatibility type.  Proceedings of the 13th
Interscience Conference on Antimicrobial Agents and
Chemotherapy. Washington: American Society for
Microbiology; 1973.
16. Deresinski SC, Pappagianis D, Stevens DA. Association
of ABO blood group and outcome of coccidioidal
infection. Sabouraudia 1979;17:261-4.
17. Mourant AE, Kopec AC, Domaniewska-Sobczak K. The
distribution of the human blood groups, and other poly-
morphisms. London: Oxford University Press; 1976. p. 230.
18. Barcellos LF. Genetic analysis of multiple sclerosis in
Caucasian and Northern Chinese populations: An
investigation of HLA and non-HLA loci. School of Public
Health [dissertation]. Berkeley (CA): University of
California; 1996.
19. Erlich HA, Zeidler A, Chang J, Shaw S, Raffel LJ, Klitz
W, et al. HLA class II alleles and susceptibility and
resistance to insulin dependent diabetes mellitus in
Mexican-American families. Nat Genet 1993;3:358-64.
20. Just JJ, King MC, Thomson G, Klitz W. African-
American HLA class II allele and haplotype diversity.
Tissue Antigens 1997;49:547-55.
21. Miller SA, Dykes DD, Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated
cells. Nucleic Acids Res 1988;16:1215.
22. Erlich H, Bugawan T, Begovich AB, Scharf S, Griffith R,
Saiki R, et al. HLA-DR, DQ and DP typing using PCR
amplification and immobilized probes. Eur J
Immunogenet 1991;18:33-55.
23. Carrington M, Miller T, White M, Gerrard B, Stewart C,
Dean M, et al. Typing of HLA-DQA1 and DQB1 using
DNA single-strand conformation polymorphism. Hum
Immunol 1992;33:208-12.
24. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1
typing by PCR amplification with sequence-specific
primers (PCR-SSP) in 2 hours. Tissue Antigens
1993;41:119-34.
25. Guo SW, Thompson EA. Performing the exact test of
Hardy-Weinberg proportion for multiple alleles.
Biometrics 1992;48:361-72.
26. Vogel F, Motulsky AG. Human Genetics. Berlin:
Springer Verlag; 1986. p. 130-1.
27. Baur MP, Danilovs J. Population genetic analysis of HLA-
A, B, C, DR, and other genetic markers. In: Terasaki PI,
editor. Histocompatibility testing 1980. Los Angeles:
UCLA Tissue Typing Laboratory; 1980. p. 955-93.
28. Long JC, Williams RC, Urbanek M. An E-M algorithm
and testing strategy for multiple-locus haplotypes. Am
J Hum Genet 1995;56:799-810.
29. U.S. Department of Health and Human Services.
United States 1996-1997 health and injury chartbook.
Hyattsville (MD): The Department; 1997. Pub. no.
(PHS) 97-1232.
30. Race RR, Sanger R. Blood groups in man. Oxford (PA):
Blackwell Scientific Publications distributed by J. B.
Lippincott; 1975.
31. Reid ME, Bird GW. Associations between human red
cell blood group antigens and disease. Transfus Med
Rev 1990;4:47-55.
32. Yamamoto F, Clausen H, White T, Marken J, Hakomori
S. Molecular genetic basis of the histo-blood group ABO
system. Nature 1990;345:229-33.
33. Gale D, Lockhart EA, Kimbell E. Studies of Coccidioides
immitis. 4. The effect of previous injection with human red
cell stromata of the ABO groups on infection of mice with C.
immitis. J Infect Dis 1968;118:54-64.
34. Greggio NA, Cameran M, Giaquinto C, Zacchello F,
Koroliuk D, Colizzi V. DNA HLA-DRB1 analysis in
children of positive mothers and estimated risk of
vertical HIV transmission. Dis Markers 1993;11:29-35.
35. Winchester R, Chen Y, Rose S, Selby J, Borkowsky W.
Major histocompatibility complex class II DR alleles
DRB1*1501 and those encoding HLA-DR13 are
preferentially associated with a diminution in
maternally transmitted human immunodeficiency
virus 1 infection in different ethnic groups: determination
by an automated sequence-based typing method. Proc
Natl Acad Sci U S A 1995;92:12374-8.
36. Chen Y, Winchester R, Korber B, Gagliano J, Bryson Y,
Hutto C, et al. Influence of HLA alleles on the rate of
progression of vertically transmitted HIV infection in
children: association of several HLA-DR13 alleles with
long-term survivorship and the potential association of
HLA-A*2301 with rapid progression to AIDS. Long-
term survivor study. Hum Immunol 1997;55:154-62.680 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
Research
37. Tiwari JL, Terasaki PI, editors. HLA and disease
associations. New York: Springer Verlag; 1985.
38. Serjeantson SW, Easteal S. Class II histocompatibility
genes and insulin-dependent diabetes mellitus.
Molecular Biology and Medicine 1989;6:219-26.
39. Kirkland TN, Finley F, Orsborn KI, Galgiani JN.
Evaluation of the proline-rich antigen of Coccidioides
immitis as a vaccine candidate in mice. Infect Immun
1998;66:3519-22.
40. Kirkland TN, Thomas PW, Finley F, Cole GT.
Immunogenicity of a 48-kilodalton recombinant T-cell-
reactive protein of Coccidioides immitis. Infect Immun
1998;66:424-31.
41. Zimmermann CR, Johnson SM, Martens GW, White
AG, Zimmer BL, Pappagianis D. Protection against
lethal murine coccidioidomycosis by a soluble vaccine
from spherules. Infect Immun 1998;66:2342-5.